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High risk types of human papillomavirus, such as type
18 (HPV-18), cause cervical carcinoma, one of the most
frequent causes of cancer death in women worldwide.
DNA replication is one of the central processes in viral
maintenance, and the machinery involved is an excel-
lent target for the design of antiviral therapy. The pap-
illomaviral DNA replication initiation protein E1 has
origin recognition and ATP-dependent DNA melting and
helicase activities, and it consists of a DNA-binding do-
main and an ATPase/helicase domain. While monomeric
in solution, E1 binds DNA as a dimer. Dimerization oc-
curs via an interaction of hydrophobic residues on a
single -helix of each monomer. Here we present the
crystal structure of the monomeric HPV-18 E1 DNA-
binding domain refined to 1.8-Å resolution. The struc-
ture reveals that the dimerization helix is significantly
different from that of bovine papillomavirus type 1
(BPV-1). However, we demonstrate that the analogous
residues required for E1 dimerization in BPV-1 and the
low risk HPV-11 are also required for HPV-18 E1. We also
present evidence that the HPV-18 E1 DNA-binding do-
main does not share the same nucleotide and amino acid
requirements for specific DNA recognition as BPV-1 and
HPV-11 E1.
Papillomavirus is classified in the Papovaviridae family of
double-stranded DNA tumor viruses, which also includes poly-
omaviruses such as SV40. There are about 100 identified pap-
illomaviruses that infect humans. The clinical lesions range
from benign warts to invasive cancers depending on the type of
human papillomavirus (HPV)1 and several host factors. Re-
cently HPV-16, -18, and other high risk HPVs have been im-
plicated as the necessary cause of cervical carcinoma, the sec-
ond most frequent cancer in women worldwide and a major
cause of death in countries that lack screening programs (1).
HPV-16 accounts for 50–60% of all cervical cancer cases and is
the predominant type in carcinomas of squamous cell origin (2).
HPV-18 accounts for 10–12% of all cervical cancers and is the
predominant type in adenocarcinomas and small cell neuroen-
docrine carcinomas of the cervix (2, 3). Adenocarcinomas are
difficult to detect by the Papanicolaou (Pap) smear, and there-
fore cancer commonly associated with HPV-18 is often associ-
ated with rapidly progressing disease and death (3). High risk
HPVs also play a role in cancers of the prostate, bladder, anus,
penis, larynx, esophagus, oral cavity, and skin. Current treat-
ment options for HPV lesions do not specifically target HPV
infection, resulting in treatment failures and disease recur-
rence and/or progression.
All types of papillomavirus are tropic for epithelial cells of
skin and mucous membranes. The 8-kilobase pair genome en-
codes for six early (E) genes, involved in viral DNA replication,
viral gene transcription, and cellular transformation, and two
late (L) genes, which form the viral capsid. Stages in the viral
life cycle are dependent on specific factors that are present in
sequential differentiated stages of epithelial cells with expres-
sion of L genes restricted to the outermost layer of differenti-
ated keratinocytes. While cervical cancer cells contain chromo-
somally integrated HPV DNA or a mixture of both integrated
and episomal DNA, in non-cancerous or premalignant warts,
the HPV genome is strictly episomal (4). HPV episomes asso-
ciate with cellular histones in a chromatin-like assembly. The
primary viral proteins expressed in the basal cells are E1 and
E2, which are both essential for initiation of papillomavirus
DNA replication in vivo (5, 6). DNA replication is one of the
central processes in viral maintenance, and the machinery
involved would be a good target for the design of antiviral
therapy at benign and premalignant stages of disease.
E1 is involved in all steps of replication initiation: origin (ori)
recognition, ATP-dependent DNA melting, and unwinding of
DNA (for a review, see Ref. 7). The protein is highly conserved
among papillomaviruses and consists of a DNA-binding domain
(DBD) and an ATPase/helicase domain. We previously deter-
mined the crystal structure of the BPV-1 E1-DBD (residues
159–303) (8) and found it to be structurally similar to the DBD
of SV40 large T antigen, although sequence conservation is
only 6%. Others have reported structural similarities with ad-
ditional viral proteins essential for DNA replication and inte-
gration, such as the DBD of the geminivirus tomato yellow leaf
curl virus Rep and the endonuclease domain of adeno-associ-
ated virus Rep (9, 10).
While monomeric in solution, full-length E1 must first bind
to the viral ori as a dimer along with a dimer of E2 (11). The
DBD of E1 alone is highly sequence-specific, but in the context
of full-length protein, which also contains the nonspecific DNA
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binding activity of the E1 helicase domain, E1 requires inter-
actions with E2 to block nonspecific E1/DNA interactions (12).
Recently inhibitors of the E1/E2 interaction have been reported
to inhibit in vivo DNA replication for low risk HPV types 6 and
11 but not for high risk HPVs (13).
Once the initial E1 dimer has been loaded by E2, more
molecules of E1 are recruited by E2 bound at a distal site to
form a tetrameric E1 complex (14). Ultimately two hexameric
E1 helicases are assembled that have ATPase activity and can
unwind the DNA (5, 14). We have also previously determined
the crystal structures of the BPV-1 E1-DBD dimer bound to
DNA and tetramer bound to DNA (15), and the ringlike hex-
americ helicase form of E1 has been visualized by electron
microscopy (16).
E1 dimerization is due to the interaction of hydrophobic
residues in the third -helix of each monomer. The interface is
small, burying only 500 Å2 of monomer surface area (8). While
the hydrophobicity of the dimer interface is conserved among
all papillomavirus types, the actual residues involved are very
poorly conserved. However, this interaction is crucial to repli-
cation initiation as mutation of one hydrophobic residue in
BPV-1 E1-DBD (Val-202 or Ala-206) or HPV-11 E1-DBD (Ala-
251) to arginine inhibits the ability of E1-DBD to bind to ori
DNA as a dimer in vitro, and in the context of full-length E1,
these mutations prevent DNA replication in vivo (8, 17).2 The
E1 dimerization interface is a logical target for the disruption
of DNA replication by a small molecule because of its limited
surface area and functional importance. In this study, we pres-
ent the structure of the E1-DBD from the high risk HPV-18 and
provide evidence that E1 dimerization via the 3 helix is con-
served, although the conformation of the 3 helix differs from
that of BPV-1 E1. This structural information is important for
the development of specific antiviral therapeutics to this clin-
ically relevant group of viruses.
E1 binds to overlapping sites in the ori in the assembly of E1
complexes (18, 19). The initial E1-DBD dimer binds coopera-
tively, as shown for BPV-1 and HPV-11, to palindromic hex-
anucleotide sites (called sites 2 and 4, see Table I) that are
separated by 3 base pairs in the ori and have the consensus
sequence ATTGTT (17, 19). These sites encompass two consec-
utive major grooves of DNA, one helical turn apart, and binding
of the E1-DBD dimer results in compression of the minor
groove and increased positive rise, twist, and slide and negative
roll of the DNA in the BPV-1 E1-DBD/DNA co-crystal structure
(15). Circular permutation assays have indicated that binding
of the BPV-1 E1-DBD dimer confers a bend of 40–50° in the
DNA (20), and hydroxy radical footprinting experiments have
demonstrated that DNA sequences extending beyond the E1
binding sites (BSs) are involved in E1 binding and DNA bend-
ing (21).
The DNA-binding region of E1 consists of the fourth -helix
and a well ordered loop, which form a continuous area on the
surface of the protein but bind separately to the two individual
strands of the DNA (15). The DNA-binding helix makes only
nonspecific phosphate backbone interactions, while the DNA-
binding loop is responsible for all base-specific contacts (15).
The residues that contact the DNA are very well conserved
between all papillomaviruses. All of the base-specific contacts
are van der Waals interactions, and they primarily involve the
thymidine in position 2 of each hexanucleotide site. One spe-
cific protein-DNA contact (shown for BPV-1) is a threonine in
the DNA-binding loop (Thr-187) with the methyl group of this
thymidine (15, 22). DNA binding is abrogated if Thr-187 is
changed to an alanine or if the thymidine in position 2 of either
E1-BS, site 2 or 4, is changed to any other base, including a
change to uridine, which removes only the methyl group. This
is the only nucleotide position that has an absolute require-
ment for a particular base (shown for BPV-1 and HPV-11) (15,
17), and this thymidine (shown in red in Table I) is in fact
conserved among many papillomavirus sequences. However,
the hexanucleotide sequence of site 2 in the HPV-18 ori devi-
ates and instead has a T-to-A transversion in position 2 (shown
in blue in Table I). In this study, we present evidence that the
thymidine in BS2 is dispensable for HPV-18 E1 DNA recogni-
tion although the thymidine in BS4 is significant, and the
threonine in the DNA-binding loop equivalent to BPV-1 Thr-
187 (HPV-18 Thr-238) is also nonessential for HPV-18 E1 DNA
binding. The differences in DNA binding may be related to the
structural differences at the HPV-18 E1 dimerization interface
and/or differences in the electrostatic potential energy surface
of the HPV-18 E1-DBD.
EXPERIMENTAL PROCEDURES
Protein Expression, Site-directed Mutagenesis, and Purification—
The plasmid for expression of the minimal HPV-18 E1-DBD (amino
acids 210–354) as a glutathione S-transferase (GST) fusion protein
with an internal thrombin cleavage site was provided by Arne Stenlund
(Cold Spring Harbor Laboratory). The plasmid encoding an additional
HPV-18 E1 fragment (amino acids 193–425) was cloned from genomic
DNA (ATCC) into the BamHI and XhoI sites of pGEX-4T-1 (Amersham
Biosciences), resulting in an N-terminal GST-tagged protein with an
internal thrombin cleavage site. Plasmids for expression of the HPV-18
E1-(193–425) fragment with N-terminal hemagglutinin (HA) or FLAG
tags were cloned by insertion of a cassette containing the respective
epitope tag between the thrombin cleavage site and the first codon of
the protein. Single amino acid substitutions were introduced in vectors
encoding untagged, HA-tagged, and FLAG-tagged HPV-18 E1-(193–
425) using the QuikChange site-directed mutagenesis kit (Stratagene)
according to the manufacturer’s instructions.
All HPV-18 E1-DBD fragments were expressed in Escherichia coli
strain BL21DE3 at 17 °C by induction with 0.4 mM isopropyl-1-thio--
D-galactopyranoside for 12 h. The proteins were purified using the
procedure described previously for the BPV-1 E1-DBD (8).
Crystallization, Data Collection, Structure Solution, and Refine-
ment—Crystals were grown by the hanging drop method at 17 °C using
a 5 mg/ml protein solution containing 20 mM HEPES, pH 7.5, 100 mM
NaCl, and 10 mM dithiothreitol and a reservoir solution consisting of2 A. Stenlund, personal communication.
TABLE I
E1 binding sites from 20 papillomaviruses
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28–30% polyethylene glycol 4000, 100 mM ammonium acetate, 100 mM
sodium citrate, pH 5.0–5.6, and 50–100 mM dithiothreitol in a 1:1
(protein:reservoir) ratio for a drop volume of 2 l. Crystals with typical
dimensions around 0.1  0.05  0.05 mm grew within 2 weeks.
Data were collected at beamline X26C at the National Synchrotron
Light Source at Brookhaven National Laboratory at 100 K by flash-
freezing crystals directly in the cryostream. See Table II for data col-
lection statistics. Diffraction data were processed and scaled with
HKL2000 (23).
The structure was solved by molecular replacement with the pro-
gram MOLREP (24) (resolution range 30–3 Å) using a search model
based on the crystal structure of the minimal E1-DBD from BPV-1
(amino acids 159–303) (8) in which non-identical residues were changed
to alanine. The initial R factor was 0.527, and the correlation coefficient
was 0.267. The B factors of the starting model were set to 19 Å2
according to the Wilson plot. The model phases were used as the
starting phases for the solvent-flattening routine of CNS (25). The
model was then refined against the data with CNS followed by iterative
model building using O (26). 5% of reflections were randomly reserved
for calculating the Rfree at all stages to monitor refinement. Several
cycles of model building and refinement allowed for the placement of
water molecules and two alternate side chain conformations to produce
the final model. The criteria for the assignment of a Fo  Fc density
peak as water is a peak height greater than 4  and a hydrogen bonding
distance between the solvent peak and any protein oxygen or nitrogen
atom between 2.5 and 3.5 Å. The water scrutinizer routine of XPAND
was used to check the validity of water molecules (27). The final model
contains clear electron density for residues 210–353 with a break in the
density from residues 231 to 239. Three residues (Gly, Ser, and Arg)
that remain on the N terminus after cleavage of the protein from GST
are not clearly visible in the electron density. See Table II for refine-
ment details. Figures were prepared with MOLSCRIPT (28), BOB-
SCRIPT (29), and Raster 3D (30, 31).
Gel Mobility Shift Assays—The 105-bp probe for gel mobility shift
assays was generated by PCR amplification of HPV-18 genomic DNA
containing the ori using a plus strand primer that was 5-labeled with
[-32P]ATP and T4 polynucleotide kinase. The probe was gel-purified by
8% non-denaturing PAGE, exposure to film, and elution of DNA from
acrylamide slices by overnight incubation in Tris-EDTA.
For DNA competition assays, 21-bp DNA containing wild type HPV-
18, mutant HPV-18, or BPV-1 E1 binding sites as found in the respec-
tive origins of replication was synthesized by Operon with the trityl
protecting group left on and purified by reverse-phase chromatography,
on-column deprotection, desalting, and ion exchange chromatography.
Competition assays were performed as described previously (32).
Serial dilutions of competitor DNA were incubated with 10 ng of
HPV-18 E1-DBD (amino acids 193–425) for 15 min at room tempera-
ture in a buffer containing 20 mM potassium phosphate, pH 7.4, 200 mM
sodium chloride to minimize nonspecific E1/DNA interactions, 1 mM
EDTA, 10% glycerol, 0.1% Nonidet P-40, 3 mM dithiothreitol, and 0.7
mg/ml bovine serum albumin. The reaction buffer for gel shift assays
with dimerization mutant proteins (data not shown) contained 100 mM
NaCl, and HA-tagged proteins were supershifted with monoclonal an-
tibody anti-HA tag (12CA5, produced and purified by the Antibody
Facility of Cold Spring Harbor Laboratory). After preincubation, the
radiolabeled probe (25,000 cpm/reaction) and 40 ng/reaction nonspecific
competitor DNA (pGEX-4T-1) were added to each reaction. Samples
were incubated at room temperature for an additional 30 min and then
were resolved by 5% PAGE 39:1 (acrylamide:bisacrylamide) in 0.5
Tris-Borate-EDTA. After electrophoresis, the gels were dried and sub-
jected to autoradiography.
Immunoprecipitation and Western Blot Analysis—Immunoprecipita-
tion of FLAG fusion proteins and associated proteins was performed
with anti-FLAG M2 affinity gel according to the manufacturer’s proto-
col (Sigma). Binding reactions and washes were carried out in 20 mM
HEPES, pH 7.5, and sodium chloride at the concentrations indicated in
Fig. 3. Proteins were eluted into Laemmli sample buffer and loaded
onto 15% SDS-polyacrylamide gels followed by transfer to Hybond-P
membranes (Amersham Biosciences) using a semi-dry transfer appara-
tus. Blocking and antibody incubations were all carried out in 5% (w/v)
nonfat milk in Tris-buffered saline with 0.1% Tween 20, and washes
were with Tris-buffered saline with 0.1% Tween 20. The primary anti-
body was anti-FLAG polyclonal (Sigma) at a concentration of 1:1000,
and the secondary antibody was goat anti-rabbit IgG (heavy  light)-
horseradish peroxidase conjugate (Bio-Rad) at a concentration of 1:3000.
Proteins were detected by incubation with Super Signal West Pico chemi-
luminescent reagent (Pierce) followed by exposure to x-ray film.
RESULTS
Overall Structure of the HPV-18 E1-DBD and Comparison
with BPV-1 E1-DBD—The minimal stable DBD in BPV-1 E1
(residues 159–303) was identified by limited proteolysis, deter-
mined by gel mobility shift analysis to have DNA binding
activity, and shown to possess a fold unique to viral ori-binding
proteins (8–10). Because the sequence identity between BPV-1
E1-DBD and the analogous E1-DBD from several high risk
HPVs, including HPV-18, is limited to 30–35% (Fig. 1A) and
because of the difference in the HPV-18 E1-BS as compared
with other papillomaviral origins of replication (Table I), we
wanted to study whether there are any structural and/or bio-
chemical differences among these proteins.
We expressed the HPV-18 E1-DBD (residues 210–354) as a
GST fusion protein, cleaved the E1-DBD from GST, and puri-
fied the protein to homogeneity. The crystal structure of
HPV-18 E1-DBD (residues 210–354), containing one molecule
in the asymmetric unit, was solved by molecular replacement
and refined to 1.8-Å resolution. As expected, the structure has
the same overall fold as the E1-DBD from BPV-1, namely a
central five-stranded antiparallel -sheet flanked by four
loosely packed -helices on one side and two tightly packed
helices on the other side (Fig. 1B). While the DNA-binding loop
was very well ordered in the BPV-1 E1-DBD monomer struc-
ture, it is disordered in the structure of the HPV-18 E1-DBD.
The BPV-1 E1-DBD monomer crystals grew from a high salt
condition, and the ions in the solution were bound to the DNA-
binding loop, mimicking some of the phosphates of a DNA
backbone, as later seen from the co-crystal structure with DNA
(15). However, the HPV-18 E1-DBD crystals grew from a low
salt condition, so this effect was not present.
The overall root mean square deviation (r.m.s.d.) between
the DBD of HPV-18 E1 and BPV-1 E1 is 1.13 Å for 132 aligned
-carbons (LSQMAN (33)). As shown in Fig. 1C, there are four
regions for which the two molecules do not superimpose as well:
the disordered DNA-binding loop (HPV-18 E1-DBD residues
231–239), an extended -hairpin of no known function (resi-
dues 272–283), a small loop of no known function (residues
334–337), and the 3 helix shown to be required for BPV-12 (8)
and HPV-11 (17) DNA-dependent E1 dimerization and replica-
tion function (residues 252–263). The HPV-18 E1-DBD 3 helix
is a residue shorter in length than the analogous BPV-1 E1-
DBD 3 helix (residues 201–213) (8). Also, as seen in Fig. 1B,
the HPV-18 E1-DBD 3 helix has an obvious kink, which is
TABLE II
Data collection and refinement statistics
Wavelength (Å) 1.1
Oscillation angle (°) 1.0
Space group C2
Cell dimensions a  70.54 Å, b  46.24 Å, c  43.19 Å
  94.01°
Resolution (Å)a 30.0–1.8 (1.91–1.8)
Observed reflections 45,127
Unique reflections 12,094 (1412)
Redundancy 3.41 (2.25)
Completenessa 93.0 (69.1)
I/(I)a 17.5 (5.7)
Rmerge
a,b 0.049 (0.135)
R factor (%) 21.3
Rfree (%) 22.2
Number of atoms (protein, solvent) 1202, 109
r.m.s.d. from bond ideality (Å) 0.009
r.m.s.d. from angle ideality (°) 1.5
Protein average B factor (Å2) 19.4
Ramachandran plot
Most favorable (%) 98.3
Additionally allowed (%) 1.7
a Numbers in parentheses are for the highest resolution shell.
b Rmerge   I I /I where I observed intensity and I  average
intensity obtained from symmetry-related and multiple measurements.
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FIG. 1. Comparison of HPV-18 and BPV-1 E1-DBD sequences and structures. A, alignment of four selected papillomavirus E1-DBD sequences
with the crystallographically determined secondary structure for HPV-18 E1-DBD on the top. As colored in B, the disordered DNA-binding loop is
indicated by the red dashed line, the 3 dimerization helix is drawn in orange, and the 4 DNA-binding helix is drawn in green. Based on an alignment
of a total of eight sequences (not shown: E1-DBD from HPV-31, -33, -12, and -5), residues that are identical among at least three sequences are
highlighted in blue, and residues that are similar are highlighted in green. HPV-18 and BPV-1 E1-DBD residues are respectively numbered. B,
The DNA-binding Domain of HPV-18 E13736
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clearly defined in the electron density, that is not present in the
BPV-1 E1-DBD. The DNA-binding helix is unchanged between
HPV-18 and BPV-1 E1-DBD.
The kink in the HPV-18 E1-DBD 3 helix is due to differ-
ences in the hydrogen (H)-bonding network (see Fig. 2). A
straight -helix retains its shape because of the backbone H-
bonding interaction between the CO group of each residue n
with the NH group of residue (n  4). In the HPV-18 E1-DBD
3 helix, there are four residues that H-bond with the NH
group of the (n  3) residue rather than the (n  4): Ile-254
with Gly-257, Ala-255 with Phe-258, Ile-262 with Phe-265, and
Gln-263 with Ile-266 (HBPLUS (34)), resulting in a partial 310
helix. In contrast, the 3 helix in the BPV-1 E1-DBD structure
consists of only (n  4) backbone H-bonding interactions of a
typical, straight -helix. The HPV-18 E1 3 helix is also stabi-
lized by a tightly bound water molecule, which H-bonds to the
CO groups of residues Ala-255 and Glu-256 and the NH groups
of residues Phe-258 and Lys-259 (XPAND (27)). However, in
the BPV-1 E1-DBD structure there is no solvent bound to 3
helix residues. Finally residue Thr-253 in the HPV-18 E1-DBD
3 helix does not participate in any H-bonding interactions
either to other residues or to solvent, whereas the equivalent
residue (Val-202) in the BPV-1 E1-DBD makes the typical (n 
4) H-bonds.
For BPV-1, there were four different interaction surfaces
between E1-DBD monomers in the E1-DBD crystal, one of
which placed the DNA-binding surfaces of each monomer ex-
actly one helical turn apart, and this was shown by mutational
analysis to constitute the natural dimer (8). This contact was
also present in several other crystal forms of BPV-1 E1-DBD.
However, for the HPV-18 E1-DBD crystals, there was no ap-
parent biologically relevant dimer from crystal packing. It
should be noted that the same 3 helix interface was not used
for lattice interactions, and therefore its different conformation
is probably not due to crystal packing forces. The difference in
the HPV-18 E1 3 helix structure and the T-to-A transversion
in the HPV-18 E1 binding site 2 (Table I) brought up the
possibility that HPV-18 E1 dimerizes and/or contacts the DNA
differently. To study E1/E1 and E1/DNA interactions, we per-
formed the experiments described below.
The 3 Helix Is Important for Multimerization of the HPV-18
E1-DBD on DNA—Fluorescence anisotropy experiments per-
formed with wild type BPV-1, HPV-11, and HPV-18 E1-DBD
showed that E1-DBD preferentially binds DNA as a dimer in
all cases (17). The surface involved in E1 dimerization was
identified for BPV-1 as the 3 helix by mutagenesis (8) and
FIG. 2. Hydrogen-bonding network of the HPV-18 E1-DBD 3
dimerization helix. Stereodiagram of the 3 helix in HPV-18 E1-
DBD. The kink in the HPV-18 E1-DBD 3 helix (in cyan) is due to
backbone (n  3) hydrogen bonds and hydrogen bonds to a water
molecule (represented by the red ball). Hydrogen bonds are indicated by
the dashed lines. The figure is rotated by 180° along the y axis with
respect to the view in Fig. 1B for clarity.
FIG. 3. Mutations at the 3 helix affect DNA-dependent dimer-
ization of HPV-18 E1-DBD in a salt-sensitive manner. A, FLAG-
and HA-tagged wild type (wt) (lanes 2–5) or 3 helix mutant HPV-18
E1-DBD (the G257R (GR) mutant is shown) (lanes 7–10) were mixed in
the presence of DNA containing HPV-18 E1-BS and a range of salt
concentrations (100–250 mM as indicated) and immunoprecipitated
with an anti-FLAG antibody. Immunoprecipitates were analyzed by
Western blot using an antibody specific for the HA tag. One-tenth of
input (IN) is shown as a loading control (lanes 1 and 6). B, co-immuno-
precipitation of FLAG- and HA-tagged wild type (wt) BPV-1 or HPV-18
E1-DBD in the presence of 100 mM salt, with and without DNA con-
taining the respective E1-BS, to show the DNA dependence of dimer-
ization. One-tenth of input (IN) is shown as a loading control.
FIG. 4. Comparison of the BPV-1 E1-DBD dimer with DNA
crystal structure with an energy-minimized model of the
HPV-18 E1-DBD dimer with DNA. Two monomers of HPV-18 E1-
DBD (cyan) were superimposed onto the BPV-1 E1-DBD dimer (ma-
genta) structure docked onto an idealized B-form DNA containing
HPV-18 E1-BS and energy-minimized with AMBER 7 (35).
ribbon diagrams of the HPV-18 (left) and BPV-1 (right) E1-DBD crystal structures, color-ramped from red at the N terminus to magenta at the C
terminus. The structures are shown side by side in the same view to appreciate the overall similarity of the fold. The disordered DNA-binding loop
for HPV-18 E1-DBD is indicated by the dashed line. C, superposition of the HPV-18 (cyan) and BPV-1 E1-DBD (magenta) -carbon traces, in the
same view as B, to show the differences between the two structures. The regions that overlay with an r.m.s.d. of greater than 2 Å are shown in
color, and regions that align well (r.m.s.d. 	 2 Å) are shown in gray. The disordered HPV-18 DNA-binding loop is indicated by the thin line.
The DNA-binding Domain of HPV-18 E1 3737
 at Cold Spring Harbor Laboratory, on M
arch 21, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
FIG. 5. Demonstration of altered nucleotide specificity for HPV-18 E1-DBD by DNA competition. A, sequences of unlabeled DNA used
to compete complexes of 10 ng of wild type (wt) HPV-18 E1-DBD (E1) with 25,000 cpm/lane of a 105-bp HPV-18 ori probe (P). Nucleotides that form
BS2 and -4, which encompass two consecutive major grooves of the DNA, are underlined. The nucleotide in position 2 of each BS is shown in bold
typeface, and mutations are indicated by italics. For each competition assay, serial dilutions of the same stock DNA competitor concentration were
used. The reactions were subjected to 5% PAGE and autoradiography. In all gels, lane 1 is the radiolabeled ori probe alone, lane 2 contains HPV-18
E1-DBD incubated with the ori probe, lanes 3–8 contain 5-fold dilutions of unlabeled HPV-18 wild type (wt) E1-BS competitor incubated with
HPV-18 E1-DBD and ori probe, and lanes 9–14 contain 5-fold dilutions of unlabeled test competitor incubated with HPV-18 E1-DBD and ori probe.
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confirmed by the crystal structure of the BPV-1 E1-DBD dimer
with DNA (15). Gel mobility shift assays with BPV-1 E1-DBD
and fluorescence anisotropy experiments for HPV-11 E1-DBD
revealed that substitution of a small hydrophobic residue in 3
helix to a bulky charged residue (e.g. A206R for BPV-1 or
A251R for HPV-11) inhibits E1 from binding DNA as a dimer
and instead promotes binding as a monomer (8, 17). The BPV-1
A206R2 and HPV-11 A251R (17) full-length E1 mutants are
also severely compromised for replication of ori-containing
plasmids in vivo. While the functional importance of E1 dimer-
ization has been demonstrated for BPV-1 and HPV-11, it has
not been shown that the analogous residues required for BPV-1
and HPV-11 E1 dimerization are involved in HPV-18 E1
dimerization.
To assess whether HPV-18 E1-DBD binds DNA as a dimer
via the same interface, the analogous substitutions in HA- and
FLAG-tagged HPV-18 E1-DBD constructs were made by site-
directed mutagenesis (G257R, I254R, and I254D). These mu-
tations do not affect proper folding of these proteins since they
were still able to bind DNA in a gel mobility shift assay,
although higher mutant protein concentrations were required
to obtain these complexes (data not shown).
E1 dimerization was assayed by mixing HA- and FLAG-
tagged wild type or mutant proteins together with DNA, im-
munoprecipitating the proteins with anti-FLAG affinity gel,
and subsequently performing Western blot analysis with an-
ti-HA antibody. To overcome possible sequence-nonspecific pro-
tein/DNA interactions, which could lead to co-immunoprecipi-
tation artifacts, the immunoprecipitation reactions were
performed in the presence of a range of salt concentrations. The
rationale was that higher salt concentrations would stabilize
hydrophobic protein/protein interactions of cooperatively
bound protein dimers at adjacent E1 binding sites, while de-
stabilizing electrostatic protein/DNA interactions of independ-
ently bound monomers. As shown in Fig. 3A, co-immunopre-
cipitation of wild type HPV-18 E1 was stably maintained at
increasing salt concentrations with an optimal NaCl concen-
tration of 200 mM (lane 4). However, co-immunoprecipitation of
the HPV-18 3 helix mutant protein G257R was unstable un-
der these assay conditions and did not occur at salt concentra-
tions greater than 150–200 mM (compare lane 8 with 3, lane 9
with 4, and lane 10 with 5). Proteins did not co-immunopre-
cipitate in the absence of DNA (Fig. 3B). The experiment was
highly reproducible (n  3), and the same result was obtained
with the other two 3 helix mutants, I254R and I254D (data
not shown). These results indicate that 3 helix mutations do
not affect the ability of independent monomers to bind DNA but
FIG. 6. Demonstration of altered residue requirements for HPV-18 E1-DBD by gel mobility shift analysis of DNA-binding loop
mutants. DNA binding activities of wild type HPV-18 E1-DBD (wt) (lanes 2–5 and lanes 15–18) and the DNA-binding loop mutants (K237A, lanes
6–9; T238A, lanes 10–13; and T239A, lanes 19–22) were assayed with a 105-bp HPV-18 ori probe (P) that contains wild type E1-BS. Four 2-fold
dilutions of the same stock concentration of each protein were used. The reactions were subjected to 5% PAGE and autoradiography. Probe alone
is shown in lanes 1 and 14. The position of the band corresponding to the complex of HPV-18 E1-DBD and ori probe is indicated by the asterisks.
In like manner to the analogous experiment performed with BPV-1 E1, the K237A mutation abolished E1 DNA binding activity, and the T239A
mutation retained DNA binding activity as compared with wild type. However, in contrast to the analogous experiment with BPV-1 E1, the T238A
mutation decreased E1 DNA binding activity as compared with wild type but did not abrogate it.
FIG. 7. Comparison of the electrostatic surface potential of the
HPV-18 and BPV-1 E1-DBD DNA-binding surfaces. A, surface
representation of HPV-18 (left) and BPV-1 (right) E1-DBD with the
residues forming the DNA-binding loop mapped in green and the DNA-
binding helix mapped in yellow. B, electrostatic potentials of the
HPV-18 (left) and BPV-1 (right) E1-DBD molecular surfaces displayed
in the same view as A as a color gradient from red (electronegative,
10 kBT) to blue (electropositive,10 kBT) where kB is the Boltzmann
constant and T is absolute temperature. These figures were drawn with
the program GRASP (37) and are rotated by 
90° along the x axis with
respect to the view in Fig. 1B to expose the DNA-binding surfaces.
The position of the band corresponding to the complex of HPV-18 E1-DBD and ori probe is indicated by the asterisks. The effect of the identical
concentration of wild type competitor is compared with that of each test competitor DNA (for each gel, compare lane 3 with 9, lane 4 with 10, lane
5 with 11, lane 6 with 12, lane 7 with 13, and lane 8 with 14). B, the relative affinity of HPV-18 E1-DBD for its own wild type (wt) E1-BS as
compared with BPV-1 wild type E1-BS is similar. C, the relative affinity of HPV-18 E1-DBD for its own wild type E1-BS as compared with a mutant
E1-BS in which the anomalous adenine in position 2 of BS2 is changed to thymidine (DNA A3 Tsite2) is similar. D, HPV-18 E1-DBD has a higher
affinity for its own wild type E1-BS than for a mutant E1-BS in which the thymidine in position 2 of BS4 is transverted to adenine (DNA T3 Asite4).
E, HPV-18 E1-DBD has a higher affinity for its own wild type E1-BS than for nonspecific DNA.
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do inhibit HPV-18 E1 dimerization and cooperative binding.
Since HPV-18 E1 dimerizes via an interface analogous to
BPV-1 and HPV-11 E1 dimers, we constructed a model of the
HPV-18 E1-DBD dimer by sequential superposition of two
monomers of the protein on the structure of the BPV-1 E1-DBD
dimer with DNA (LSQMAN (33)). In this model, each disor-
dered DNA-binding loop was built in a conformation similar to
that of BPV-1 E1. The HPV-18 E1-DBD dimer model was
subsequently subjected to two rounds of energy minimization
to relieve steric clashes (AMBER 7 (35)). This minimized
HPV-18 model is shown in Fig. 4 in comparison with the crystal
structure of the BPV-1 E1-DBD dimer complex with DNA (15)
to demonstrate the obvious structural differences at the dimer-
ization interface.
Affinity of the HPV-18 E1-DBD for Its Cognate Origin, BPV-1
E1 Binding Sites, or Mutant Sites—Sequence alignment of the
respective origins of replication from HPV-18, other HPV types,
and BPV-1 E1-BS revealed a potential difference in HPV-18 E1
DNA recognition (Table I). The only invariant base in the
E1-BS (as shown for BPV-1 and HPV-11) is the conserved
thymidine in position 2 of each BS (15, 17). However, as shown
in Table I, the HPV-18 E1-BS has a T-to-A transversion at this
position in BS2. We resequenced the HPV-18 ori several times
and confirmed that the T-to-A transversion is indeed present in
the HPV-18 E1-BS (data not shown).
When we superimposed the energy-minimized HPV-18 E1-
DBD dimer model (Fig. 4) on the BPV-1 E1-DBD dimer struc-
ture, we observed a major difference in the alignment of the
DNA-binding loops of each HPV-18 E1-DBD monomer (LSQ-
MAN (33)) (data not shown). For the monomer in the HPV-18
E1-DBD dimer model that binds to E1-BS4 containing the
invariant thymidine, the only -carbons of the DNA-binding
loop that do not superimpose well (r.m.s.d. 2 Å) correspond to
residues Lys-237 and Thr-238 (equivalent to BPV-1 Lys-186
and Thr-187). The -carbons of the other residues of the DNA-
binding loop in this monomer remained close to the conforma-
tion of the BPV-1 DNA-binding loop. In contrast, the monomer
that binds to E1-BS2, which contains the T-to-A transversion,
has a total of five adjacent -carbons (residues 235–239) in the
DNA-binding loop that do not align well with the equivalent
BPV-1 E1-DBD -carbons (residues 184–188). The -carbons of
these five residues are also positioned differently as compared
with the DNA-binding loops in the HPV-18 input model used
for energy minimization. The discrepancy between DNA-bind-
ing loops of HPV-18 E1-DBD monomers suggests that the
HPV-18 E1-DBD dimer may bind to E1-BS2 and -BS4 in an
asymmetric fashion.
To study HPV-18 E1-DBD DNA sequence specificity, we
performed gel mobility shift assays in which E1ori probe com-
plexes were competed with unlabeled DNA. Sequences of com-
petitor DNA are shown in Fig. 5A. E1 and DNA were incubated
in the presence of 200 mM NaCl as we had determined in the
immunoprecipitation experiments described above that this
salt concentration optimizes specific E1/DNA interactions and
minimizes sequence-nonspecific interactions. Similar relative
affinities were obtained when competition was performed with
HPV-18 wild type E1-BS compared with BPV-1 wild type
E1-BS (Fig. 5B) or compared with mutant HPV-18 E1-BS in
which the deviant adenine in position 2 was reverted back to
the conserved thymidine (Fig. 5C) as the same concentration of
each competitor DNA was required to achieve the same degree
of competition (for both gels, compare lane 3 with 9 and lane 4
with 10). However, a mutant HPV-18 E1-BS in which an addi-
tional T-to-A transversion is introduced in position 2 of BS4
demonstrated a significantly diminished capacity to compete
E1ori complexes as compared with wild type HPV-18 E1-BS
(Fig. 5D, compare lane 9 with 3 and lane 10 with 4), suggesting
that the thymidine in this site is important to DNA recognition.
The binding of HPV-18 E1-DBD to the labeled probe was not
competed with nonspecific DNA in the same concentration
range as specific competitors (Fig. 5E, compare lane 9 with 3
and lane 10 with 4). These experiments indicate that in con-
trast to BPV-1 E1, which requires thymidine in position 2 of
both BS2 and BS4 for DNA binding, sequence-specific HPV-18
DNA recognition is dependent only on the thymidine in BS4.
Residue Requirements in the HPV-18 E1 DNA-binding
Loop—The crystal structure of the BPV-1 E1-DBD dimer in
complex with DNA revealed that, as in most DNA-binding
proteins, E1/DNA interactions are mostly electrostatic. How-
ever, unlike most DNA-binding proteins, all base-specific con-
tacts in this case are van der Waals interactions. These base-
specific contacts all involve residues of the DNA-binding loop,
and most are to the thymidine in position 2 of each hexanucle-
otide site (15). The role of the BPV-1 DNA-binding helix in
nonspecific DNA contacts is supported by the tolerance for
mutational changes in this -helix (36). However, mutational
analysis of the BPV-1 E1 DNA-binding loop revealed that in
addition to several charged residues (Arg-180, Lys-183, and
Lys-186), one threonine in the loop (Thr-187) is also critical for
DNA binding, while the neighboring threonine (Thr-188) is not
(22). Thr-187 was shown in the crystal structure of the BPV-1
E1-DBD dimer and tetramer with DNA to be one of the major
contacts of the invariant thymidine in position 2 of the E1-BS
(15).
To see whether there is a difference in residue requirements
for HPV-18 E1 DNA binding, we cloned and purified the equiv-
alent DNA-binding loop mutant proteins (HPV-18 K237A,
T238A, and T239A equivalent to BPV-1 Lys-186, Thr-187, and
Thr-188) and performed the analogous gel mobility shift assay.
Serial 2-fold dilutions of the same stock protein concentrations
were tested for ori binding activity. As evident in Fig. 6, a
mutation of Lys-237 to alanine completely abrogated HPV-18
E1 DNA binding activity (compare lanes 6–9 with lanes 2–5).
This parallels the result that was obtained with the equivalent
BPV-1 K186A mutant. Similarly the HPV-18 T239A mutant
retained wild type DNA binding activity (compare lanes 19–22
with lanes 2–5), which also parallels the result obtained for the
equivalent BPV-1 mutant (T188A). However, while the BPV-1
T187A mutation completely abolished DNA binding activity,
the equivalent HPV-18 T238A mutation showed only a reduc-
tion in ori binding (compare lanes 10–13 with lanes 2–5). This
result may be related to the loss of the thymidine requirement
in position 2 of the HPV-18 E1-BS.
DISCUSSION
In the present study we describe structural and biochemical
studies of E1-DBD from a clinically relevant, high risk human
papillomavirus (HPV-18) that may facilitate the development
of targeted antiviral agents at benign and premalignant stages
of disease. The E1 dimerization interface is a logical target for
the disruption of DNA replication by a small molecule because
of its limited surface area and importance for binding of E1 to
DNA and for viral DNA replication. However, to date there are
no reported structures of the E1-DBD from any HPV.
Here we describe the structure refined to 1.8-Å resolution of
the E1-DBD from HPV-18 and show that one major structural
difference in comparison with the BPV-1 E1-DBD lies in the 3
helix, which forms the E1 dimerization interface. In the
HPV-18 E1-DBD, the 3 helix is kinked due to (n 3) backbone
H-bonding interactions and a tightly bound solvent molecule,
resulting in a partial 310 helix, while the BPV-1 E1-DBD 3
helix retains the (n  4) H-bonding network of a typical helix
with no bound solvent. Because of this difference in one of the
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key functional elements of the protein, immunoprecipitation
experiments were performed to demonstrate that the analo-
gous residues required for BPV-1 and HPV-11 E1 dimerization
are also required for HPV-18 E1 dimerization. This structural
difference is relevant to drug design at the E1 dimerization
interface and may also play a role in stability of HPV-18
E1DNA complexes by forming tighter dimers and/or position-
ing the DNA binding elements differently as compared with
BPV-1 E1.
Importantly the HPV-18 E1-BS has a T-to-A transversion in
an otherwise invariant nucleotide position (Table I). In addi-
tion, the DNA-binding loop of HPV-18 E1-DBD was disordered
in the crystal structure. Therefore, we performed gel mobility
shift assays to study the nucleotide sequence and residue re-
quirements for HPV-18 E1 DNA binding. We found that
HPV-18 E1-DBD does not share the same requirements for
DNA recognition as BPV-1 and HPV-11 E1 (Figs. 5 and 6). The
thymidine in position 2 of BS2 and the threonine that was
shown for BPV-1 to be the major contact of this nucleotide are
both nonessential for HPV-18, although the thymidine in posi-
tion 2 of BS4 does play a role in HPV-18 E1 DNA recognition.
However, discrimination of E1-BS does not just rely on direct
base contacts. Other key determinants of E1-BS recognition
include electrostatic interactions and structural features of
DNA such as backbone flexibility. The BPV-1 E1-DBD was
shown to distort the DNA in co-crystal structures and biochem-
ical studies (15, 20), and this E1-induced DNA deformation
involves additional stretches of sequence outside the E1-BS
(21). While these flanking regions demonstrated tolerance for
mutations, suggesting that these contacts are phosphate back-
bone interactions and not base-specific, the contacts are none-
theless critical for stabilizing the E1DNA complex and bending
the DNA around the protein (21). The contacts within the
E1-BS were also shown to be primarily nonspecific phosphate
backbone interactions with mutational tolerance (15, 36). Be-
cause of the predominance of electrostatic interactions in
BPV-1 E1 DNA binding, we mapped the electrostatic potential
of the DNA-binding surfaces of the BPV-1 and HPV-18 E1-DBD
for comparison. For HPV-18 E1-DBD, the disordered DNA-
binding loop was modeled in a conformation similar to that of
BPV-1 E1. As shown in Fig. 7, the shapes and locations of the
charged patches of surface potential are different for BPV-1
and HPV-18, suggesting specific energetic coupling between
each protein, its respective BS, and the flanking DNA.
There is evidence from BPV-1 that E1 also has a sequence-
dependent structural requirement in the DNA. The BPV-1
E1-BS was observed to contain a 2-fold symmetrical pattern of
the most kinkable pyrimidine-purine steps (TG, CA, and TA) at
three base intervals (15). The increased positive rise, twist, and
slide of the DNA and the highly negative roll observed in the
BPV-1 E1-DBDDNA complex structures were most pro-
nounced at the central dinucleotide step (15). However, this
same pattern of pyrimidine-purine steps is not completely con-
served among all the other papillomavirus E1-BS sequences as
every HPV sequence lacks at least one kinkable dinucleotide
step (see Table I). The role of flexible dinucleotide steps in other
E1-BSs, as studied by mutational tolerance in HPV-11, is un-
clear (17). It is interesting to note that for the HPV-18 E1-BS,
the symmetrical, regularly spaced pattern of pyrimidine-pu-
rine steps as found in BPV-1 is maintained except for the
central dinucleotide step, which is a rigid purine-purine. The
rigid central dinucleotide step and the T-to-A transversion in
E1-BS2 may both alter the kinkability and conformation of the
HPV-18 E1-BS. There may be different requirements for local
DNA flexibility for HPVs as compared with BPV-1 because,
while in HPV origins of replication the E1- and E2-BS are
distal (over 30 bp apart), in BPV-1 the E1- and E2-BS are
proximal (only 3 bp apart). As a result, there is a required
additional interaction in BPV-1 between the DBDs of E1 and
E2 that does not occur in HPV (38). This interaction induces a
sharp bend in the BPV-1 ori (120–130°) and facilitates the
productive interaction between the BPV-1 E1 helicase domain
and E2 activation domain (20).
It was presented here that the DNA-binding loop in the
HPV-18 E1-DBD structure is disordered when unbound, so
the conformation of the loop is unknown. It is possible that the
residues of the HPV-18 E1 DNA-binding loop could shift posi-
tion to accommodate variations in geometric parameters of the
DNA as compared with BPV-1 E1. Our energy-minimized
model of the HPV-18 E1-DBD dimer in complex with DNA (Fig.
4) suggests that HPV-18 E1 DNA recognition may be asymmet-
ric as the conformation of the DNA-binding loop of each mon-
omer is not entirely superimposable.
Taken together, several features of HPV-18 E1-DBD may
contribute to the complementarity between the protein and its
E1-BS: the kinked 3 helix, the conformation(s) for the DNA-
binding loops of each monomer in the dimer, and the electro-
static potential of the DNA-binding surface. As variations in
the sequence-specific kinkability of the E1-BS DNA and flank-
ing sequences can also contribute to complementarity, E1 ori
recognition likely involves an indirect readout mechanism as
well. Indirect readout, a reliance on structural features of DNA,
has been hypothesized as a mechanism of DNA recognition for
a number of other DNA-binding proteins (39), including the
papillomavirus E2 protein (40). A more detailed understanding
of the interaction between HPV-18 and its binding site await
further structural studies of a complex between the two.
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